KLK3 and prostate carcinoma: Recent findings from a decade-long study involving 415,000 British men (The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) Randomized Clinical Trial) have not supported single PSA testing for population-based screening and suggest that asymptomatic men should not be routinely tested to avoid unnecessary anxiety and treatment.